Tämän luulisi kelpaavan markkinalle 
Hims & Hers and Novo Nordisk Team Up to Expand Affordable Access to Care
April 29, 2025
A bundled offering of Novo Nordisk’s FDA-approved Wegovy® on the Hims & Hers platform marks the first step in a long-term collaboration roadmap, pairing innovative treatments with a leading care platform to elevate the impact of obesity care for today’s consumer.
SAN FRANCISCO–(BUSINESS WIRE)-- Novo Nordisk and Hims & Hers Health, Inc. (NYSE: HIMS) today announced a long-term collaboration designed to make proven obesity care and treatments more accessible, more affordable, and more connected for millions of Americans.
A bundled offering of Novo Nordisk’s FDA-approved Wegovy® on the Hims & Hers platform marks the first step in a long-term collaboration roadmap, pairing innovative treatments with a leading care platform to elevate the impact of obesity care for today’s consumer.
As a first step, Americans can now access NovoCare® Pharmacy directly through the Hims & Hers platform, with a bundled offering of all dose strengths of Wegovy® and a Hims & Hers membership, which includes access to 24/7 care, ongoing clinical support, and nutrition guidance, all in one place. At a single, unified price starting at 599 USD per month, individuals may be prescribed Wegovy®, alongside Hims & Hers’ world-class, holistic approach to care, powered by today’s technology. The offering is available this week on the Hims & Hers platform.
The companies are also developing a roadmap that combines Novo Nordisk’s innovative treatments with Hims & Hers’ ability to scale access to quality care, aiming to improve long-term outcomes for more people, more affordably.
